MS4A1 and B-cell chronic lymphocytic leukemia: Currently, there are no trials comparing targeted agents directly and the preferred regimens in the setting of treatment naïve (TN) and r/r TP53 disrupted CLL consist of a single small molecule inhibitor +/− anti-CD20 therapy at either indefinite or fixed-duration dosing [5].